International Journal of Clinical Research

Objective To analyze the intervention effect of acarbose treatment on diabetes in community. Methods: 280 patients with diabetes diagnosed and treated in the community in the past two years (January 2020 February 2022) were selected. The clinical data were reviewed. 140 patients who were treated with acarbose were selected as the observation group and 140 patients who were treated with conventional therapy were selected as the control group. The clinical effects of the two groups were compared. Results: After treatment, the fasting blood glucose (6.28 ± 2.11) mmol/L, blood glucose (8.04 ± 2.38) mmol/L, and glycosylated hemoglobin (6.42 ± 0.62) mmol/L in the observation group. In the control group, fasting blood glucose (8.89 ± 2.28) mmol/L, blood glucose (10.86 ± 3.24) mmol/L, and glycosylated hemoglobin (8.89 ± 0.95) mmol/L at 2h after meal were observed. The difference between groups was statistically significant (P<0.05); The total effective rate was 93.57% in the observation group and 88.57% in the control group. The difference between groups was statistically significant (P<0.05); During follow-up, it was found that the adverse reaction rate of the observation group was 5.71%, and that of the control group was 2.86%. There was no significant difference between groups (P>0.05). Conclusion: adding acarbose to diabetes patients in the community can control the blood sugar level to a great extent, improve the treatment effect, help to improve their quality of life, and have definite clinical application value.

Community; Diabetes; Acarbose; Blood glucose index; Adverse reactions; effect